Clobex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clobex

Quick Facts

Property Description
Active ingredient Clobetasol propionate
Form Topical Solution (Scalp Solution)
Pharmacological class Super-high Potency Corticosteroid (Class I)
Route of administration Topical
Origin Synthetic

What Type of Medicine is Clobex and Its Active Component?

Clobex is a prescription-only medication featuring the single active ingredient clobetasol propionate, a compound formally classified as a synthetic corticosteroid and belonging to the broader Glucocorticoid pharmacological class. Clinical practice and pharmacological studies recognize clobetasol propionate as a super-high potency or Class I topical agent, representing the highest tier of strength available for external dermatological use. This high classification is supported by numerous pharmacological studies and is critical for treating highly active inflammatory skin presentations where rapid action is required. This compound is entirely synthesized, not derived from natural sources.

Clobex Composition and Pharmaceutical Form

The pharmaceutical form of Clobex is specifically a Topical Solution, making it distinct from the more common steroid creams or ointments. This preparation is intended for direct application to the skin or scalp via the topical route of administration. The solution is a single-ingredient product, utilizing an emollient vehicle that often contains components such as isopropyl alcohol to effectively dissolve and deliver the clobetasol propionate. The liquid, non-aqueous composition is a key feature, chosen for its ability to penetrate and spread efficiently across hair-bearing areas like the scalp while minimizing residue.

The General Purpose of This Potent Topical Agent

The general purpose of this potent topical agent is to achieve strong, rapid relief from the intense inflammation and discomfort associated with severe inflammatory skin conditions. This utility is the direct result of its powerful anti-inflammatory and localized immunosuppressive actions. The medicine is fundamentally designed to quickly interrupt the underlying pathological cascade, a mechanism that is clinically recognized for stabilizing highly active inflammatory areas. By calming these severe responses, the medicine's core function is to alleviate symptoms including severe pruritus (itching), scaling, and excessive redness.

Regulatory References

  1. Clobetasol Propionate Topical Solution Monograph

What side effects are possible with Clobex?

Possible Side Effects and Safety Information

Clobex (clobetasol propionate) is a highly potent topical corticosteroid, and its safety profile, as documented in regulatory sources, centers on managing the risks of systemic absorption and local skin effects.

Systemic and Serious Reactions

The primary serious risk is the potential for systemic absorption, which can lead to Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. This effect can cause clinical glucocorticosteroid insufficiency, Cushing's syndrome, and hyperglycemia. These systemic effects are more likely with use over large surface areas, prolonged periods, or under occlusive dressings.

Ocular disorders such as an increased risk of glaucoma and posterior subcapsular cataracts have been reported with topical corticosteroid use; contact with the eyes should be avoided.

Local Adverse Reactions

Adverse reactions reported in clinical trials and post-marketing experience are often local in nature.

Classification Examples of Documented Reactions
Common (e.g., in trials) Skin burning sensation, pruritus (itching), skin discomfort, folliculitis
Local Skin Effects Skin atrophy (thinning), telangiectasia (spider veins), striae (stretch marks), dryness, irritation, acneiform eruptions, hypopigmentation, allergic contact dermatitis
Post-marketing Adrenal suppression, Cushing’s syndrome, eye pain, blurred vision, erythema, aggravation of psoriasis

Safety Restrictions and Considerations

The medicine should not be used on the face, axillae (armpits), or groin. It is also not indicated for the treatment of rosacea or perioral dermatitis. Treatment duration is generally restricted to a limited number of consecutive weeks (e.g., 2 or 4 weeks, depending on the specific formulation and condition) to mitigate the risk of HPA axis suppression, and the total weekly dosage must not exceed regulatory limits (e.g., 50g per week).

Pediatric patients are considered more susceptible to systemic toxicity, including HPA axis suppression and Cushing's syndrome, due to their higher skin surface area to body mass ratio.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with topical clobetasol propionate (the active ingredient in Clobex) is primarily a risk associated with chronic misuse, application to a large body surface area, use under occlusion, or exceeding recommended limits. Unlike an acute ingestion overdose, the main concern is systemic absorption leading to effects associated with prolonged exposure to high levels of corticosteroids.

Documented Overdose Risks and Manifestations

Official regulatory information describes potential systemic risks that develop over time:

  • HPA Axis Suppression: Chronic overdose or misuse can lead to the suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis, resulting in conditions like glucocorticoid insufficiency (adrenal suppression).
  • Hypercortisolism: Systemic effects can also manifest as hypercortisolism, or Cushing’s Syndrome-like features, due to excessive circulating steroid levels.
  • Pediatric Risk: Children may be more vulnerable to systemic toxicity and HPA axis suppression because of their larger skin surface-to-body mass ratio, increasing the amount of drug absorbed relative to their weight.

When to Seek Emergency Medical Attention

Immediate emergency medical attention is required in the following circumstances:

  1. Ingestion: If Clobex is accidentally swallowed, contact a poison control center or emergency services immediately.
  2. Symptoms of Systemic Overexposure: If chronic use or misuse leads to the development of features consistent with hypercortisolism (such as easy bruising, unusual weight gain, or fat deposits around the face/neck) or adrenal insufficiency (such as fatigue, dizziness, or vomiting), medical advice must be sought immediately. Management for chronic overdose, if necessary, involves gradual discontinuation of the medication under strict medical supervision to prevent acute withdrawal symptoms.

Therapeutic Uses of Clobex

Quick Facts

  • Condition: Moderate to severe plaque psoriasis
  • Condition: Scalp psoriasis (moderate to severe forms)
  • Benefit: May assist in providing relief from inflammation
  • Benefit: May assist in providing relief from itching

Clobex is an available prescription medication indicated for the topical management of certain skin conditions in adults. The primary therapeutic use is for the treatment of moderate to severe plaque psoriasis, which is a condition characterized by raised, scaly patches on the skin. Clobex may be prescribed for use on various body areas, depending on the formulation.

Additionally, one specific formulation is indicated for the targeted treatment of moderate to severe scalp psoriasis. In its approved uses, the medication works to influence the inflammatory and pruritic (itchy) manifestations of these corticosteroid-responsive dermatoses.

The application of Clobex may assist in achieving relief from symptoms such as swelling, redness, and itching associated with these conditions. It is important to note that the use of this product should be conducted under the direction of a qualified healthcare professional.

Eligibility and Restrictions for Use

Eligibility for Clobex Use

Clobex is an FDA-approved prescription medication for use only in adults 18 years of age and older. Regulatory documents provide strict limitations and contraindications based on age, application site, and pre-existing conditions.

Population Group Eligibility Status (Regulatory Basis)
Age Restriction Not Recommended for patients under 18 years due to numerically high rates of HPA axis suppression.
Hypersensitivity Contraindicated in patients with a known allergy to clobetasol propionate, other corticosteroids, or any formulation component.

Official Restrictions on Use

The medicine is contraindicated for treating specific skin issues, including rosacea and perioral dermatitis. Use is not recommended on the face, groin, or axillae (underarms), or on skin where atrophy (thinning) is present. Caution is advised for pregnant or breastfeeding women, with use considered only if the potential benefit justifies the potential risk. Systemic absorption may necessitate monitoring for conditions such as Cushing's syndrome and HPA axis suppression.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — Official regulatory information for Clobex

Interaction scope Official Regulatory Documentation
Medicinal product categories with documented interactions Strong Cytochrome P450 3A4 (CYP3A4) inhibitors and other corticosteroid-containing products (topical or systemic).
Specific interacting medicines (if explicitly listed) Ritonavir and Itraconazole are explicitly cited as examples of CYP3A4 inhibitors that interact with the active ingredient.
Mechanistic basis of interactions (only if stated in label) Inhibition of CYP3A4-mediated metabolism and a clear pharmacodynamic additive effect from other steroids.
Timing-based interaction rules (if applicable) None documented in official prescribing information.
Population-specific interaction notes (if applicable) No specific drug–drug interaction modification is explicitly documented for a particular patient population.
Interaction-related restrictions Restriction related to the co-administration of other corticosteroid-containing products due to cumulative exposure risk.
Interaction classifications (high-level) Official Regulatory Documentation
Interaction severity classification (as defined in official documents) Classified as clinically significant interactions due to the potential for increased systemic exposure.
Regulatory basis U.S. Food and Drug Administration (FDA) Prescribing Information and European Summary of Product Characteristics (SmPC) documentation.
Interaction-context constraints (as defined in official documents) The interaction status with herbal products and supplements is officially noted as not established.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with potent CYP3A4 inhibitors results in a pharmacokinetic interaction that impedes clearance and increases the systemic exposure of Clobetasol Propionate.
  • The use of more than one corticosteroid-containing product (topical or systemic) increases the total systemic corticosteroid exposure due to an established pharmacodynamic additive effect.
  • No specific drug–drug contraindications are listed in the official prescribing information, and no mandatory timing separation rules are documented.
  • The interaction status with food or herbal products has not been established in regulatory labeling and is therefore not definitively classified.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product’s interaction structure primarily through two exposure-altering pathways: the metabolic inhibition of CYP3A4 by specific drugs and the additive systemic load from other corticosteroids. This profile is further characterized by the official regulatory position that no established interaction data is available for herbal remedies, setting a boundary for undocumented substances.

Mechanism of Action

Clobetasol Propionate, a synthetic corticosteroid, modulates key physiological responses by acting on intracellular receptors to modulate activity within inflammatory signaling cascades.

Direct Modulation of Genomic Transcription

This mechanism initiates when the drug acts as a high-affinity agonist for the intracellular Glucocorticoid Receptor (GR), initiating a complex that translocates to the cell nucleus to modulate gene expression. This results in the suppression of genes that produce pro-inflammatory mediators and the upregulation of genes that produce anti-inflammatory proteins, starting the modulatory process at the core molecular level.

Interruption of the Eicosanoid Pathway

The primary downstream action of the drug's genomic modulation is the synthesis of the protein Annexin A1 (Lipocortin-1), which indirectly inhibits the enzyme Phospholipase A2 (PLA2). By blocking PLA2, the drug drastically reduces the release of Arachidonic Acid, thereby limiting the necessary precursor for synthesizing eicosanoid mediators like prostaglandins and leukotrienes.

Physiological Vasoconstriction and Cellular Suppression

The combined molecular action produces distinct physiological consequences at the application site, including localized vasoconstriction (narrowing of dermal blood vessels) and the suppression of local immune cell function (T-lymphocytes and macrophages). This reduces fluid leakage and the recruitment of inflammatory cells, influencing the local physiological response within the affected pathway.

Dosage and Administration Information

Clobex (clobetasol propionate 0.05%) is officially administered exclusively via the topical route and is intended for external use only. The medicine must be applied as a thin film solely to the affected areas, and application is strictly forbidden on sensitive regions such as the face, underarms (axillae), or groin.

The dosing schedule is determined by the specific pharmaceutical form. For Clobex Shampoo, the general principle is application once daily to the dry scalp, where it is mandated to be left in place for 15 minutes before rinsing. Other topical solutions are commonly prescribed for twice-daily use. Regardless of the form, the total amount of clobetasol propionate applied must not exceed 50 grams (or 50 mL) in one week.

Usage is limited to short, defined courses to maintain a standardized administration profile. Treatment with the shampoo formulation should be restricted to a maximum of four consecutive weeks; for other preparations, the course limit may be shorter. The therapy is intended to be discontinued once the prescribed duration is completed.

Official guidelines specify age constraints for use. Use in patients under 12 years of age is not recommended for some topical forms, while use of the shampoo formulation is not recommended for patients younger than 18 years of age. Furthermore, instructions state that the treated area should not be bandaged or otherwise covered (occluded) unless explicitly directed.

Recent Clinical Evidence

Clobex: Recent Clinical Evidence

Clobex, a formulation of the highly potent topical corticosteroid clobetasol propionate 0.05%, has been studied extensively for the management of various corticosteroid-responsive dermatoses. Clinical trials primarily focus on evaluating its application in moderate to severe plaque psoriasis in adults.

Efficacy in Plaque Psoriasis

Controlled, randomized studies involving clobetasol propionate spray for scalp psoriasis have investigated its effect on symptom severity. In a key 4-week trial, a significantly higher percentage of patients using the spray achieved treatment success (defined as clear or almost clear) compared to those using a vehicle (placebo) spray.

These studies assess changes in the Global Severity Score (GSS) of psoriasis, which measures erythema (redness), scaling, and plaque thickness. For the scalp, research has also explored the benefit of twice-weekly application for maintaining improvement after initial daily treatment.

Safety and Systemic Absorption

Due to its high potency, clinical research also focuses on the potential for systemic absorption, specifically evaluating Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. HPA axis suppression, a potential side effect of potent topical steroids, has been observed in some adult patients using clobetasol propionate, even at low doses. The risk is generally linked to prolonged use, application over large body surface areas, or the use of occlusive dressings. Researchers periodically monitor plasma cortisol levels using the Cosyntropin Stimulation Test to assess this effect, noting that suppression is often transient and reversible upon discontinuation or reduction of treatment.

Frequently Asked Questions (FAQ)

Common questions about Clobex (FAQ)

Q: What is the difference between Clobex shampoo and Clobex spray?

Official product information states that different Clobex formulations are approved for different uses and have distinct dosing instructions. For example, Clobex Spray is typically indicated for plaque psoriasis affecting up to a specific body surface area. Clobex Shampoo is generally indicated for moderate to severe forms of scalp psoriasis.

Q: Can Clobex be used to treat skin conditions other than scalp psoriasis?

Yes, Clobex in its various topical forms (such as lotion, cream, or spray) is approved for the relief of inflammatory and itchy symptoms of several corticosteroid-responsive skin conditions. This is in addition to its use for scalp psoriasis, which is one of its primary indications.

Q: Are the ingredients in Clobex products the same as generic clobetasol propionate?

The active ingredient, clobetasol propionate, is the same in Clobex brand products and their generic equivalents. However, regulatory documents indicate that the inactive ingredients, also known as excipients or the solution vehicle, may differ between Clobex and other manufacturers' products. This difference can sometimes affect the product's physical properties or how it is applied.

Q: What is HPA axis suppression and is it a potential risk with Clobex use?

HPA axis suppression is a known risk associated with the systemic absorption of highly potent topical steroids. This effect relates to the hypothalamic-pituitary-adrenal glands and can lead to adrenal gland problems, such as glucocorticosteroid insufficiency. Severe systemic effects described in regulatory sources can include the development of Cushing's syndrome and high blood sugar levels.

Q: How long does it usually take to see improvement after starting Clobex?

Official studies and clinical trial data indicate that a patient may begin to notice improvement in symptoms like inflammation and itching relatively quickly. This initial relief may begin within the first one to three days after starting treatment.

Q: What happens if Clobex is used for longer than the recommended time frame?

According to official regulatory documents, use over prolonged periods increases the risk of serious side effects from systemic absorption. The risk of developing severe local skin effects, such as skin thinning (atrophy) or stretch marks (striae), also increases with prolonged use.

Q: Why is Clobex not recommended for use on the face, groin, or armpits?

Official product warnings state that the medicine is not recommended for sensitive areas like the face, groin, or armpits. These areas are prone to increased absorption of the medication through the skin. This greater absorption increases the risk of local adverse effects, such as skin thinning (atrophy) or the formation of spider veins (telangiectasia).

Q: Does Clobex interact with other topical medications applied to the body?

The official label focuses on interactions with other corticosteroid-containing products, as their combined use increases systemic exposure. Official information advises that any additional product used should be non-medicated to help avoid potential drug interactions, as the status with other topical medicines is not always established.

Q: Why do some forms of Clobex have a flammability warning?

Some formulations of the medicine, such as the spray or foam, carry a flammability warning on the label. This is due to the composition of the product's vehicle or carrier agent, which often contains flammable substances like alcohol. For this reason, official warnings advise avoiding contact with fire, flame, or smoking during and immediately following application.

Q: What should be done if Clobex accidentally gets into the eyes?

Regulatory instructions emphasize avoiding contact with the eyes. If Clobex accidentally gets into the eyes, the official patient information advises rinsing the area immediately and thoroughly with a large amount of water.

Q: Does Clobex affect hair color or dyed hair?

Information from post-marketing reports indicates that changes in hair color have been reported as an adverse reaction associated with the use of this product.

Q: Can Clobex be applied to broken or infected skin?

Official warnings state the product is not for use on broken skin or skin areas that have cuts, scrapes, burns, or ulcerous wounds. The medicine is also contraindicated for skin areas affected by certain bacterial, fungal, or viral diseases because the corticosteroid can suppress the immune response.

Q: What are the signs of an allergic reaction to Clobex?

Signs of a serious allergic reaction, as described in regulatory documents, may include sudden swelling of the lips, mouth, throat, or tongue, and difficulty breathing. Allergic contact dermatitis, which is a localized skin reaction, is also a reported adverse reaction.

Q: Can using Clobex for a long time lead to a reaction when stopping the medication?

Official patient guidance confirms that if the medication is used for a prolonged duration, there is a risk of a skin reaction upon discontinuation. This is sometimes referred to as a topical steroid withdrawal reaction. Symptoms may include burning or increased redness in the treated area after stopping the medicine.

Q: Why is Clobex not indicated for conditions like acne or rosacea?

The medicine is not recommended for use in patients with acne vulgaris, rosacea, or perioral dermatitis. Official regulatory warnings state this restriction because the potent corticosteroid ingredient may aggravate or worsen these specific skin conditions.

Q: Does Clobex need to be rinsed off after a certain period of time?

The official instructions for Clobex Shampoo advise leaving the product on the scalp for 15 minutes before rinsing it off. In contrast, other topical formulations, such as the solution or spray, are generally designed to be gently rubbed in and left on the skin, unless otherwise specified by a healthcare provider.

Q: Can a regular shampoo be used in addition to Clobex on the same day?

Official patient information for Clobex Shampoo states that a non-medicated shampoo may be used if desired, even though the medicated shampoo itself is sufficient for cleansing. Official information advises that any additional product used should be non-medicated to help avoid potential drug interactions.

Q: What is the difference between Clobex shampoo and other clobetasol propionate foams?

Official documents detail differences in dosing schedule and treatment duration between various clobetasol propionate forms. For instance, Clobex Shampoo is typically applied once daily for up to four consecutive weeks. Other potent foam formulations may be applied twice daily for a shorter period, such as two weeks.

Q: Can Clobex use affect the results of other lab tests?

Studies and official documents indicate that the medicine's systemic effects can impact certain laboratory results. Due to the potential for HPA axis suppression and high blood sugar (hyperglycemia), the use of Clobex can affect blood and urine test results related to these conditions.

Q: What happens if a dose of Clobex is missed?

Official patient information contains specific guidance for a missed dose. These instructions typically advise what steps to follow if a dose is missed, such as applying it when remembered or skipping it if the next scheduled dose is near.

Q: Is there any evidence that Clobex can cause weight gain?

Weight gain is not listed as a common side effect of the medicine itself. However, rapid or sudden weight gain is described as one of the possible signs of a serious systemic side effect called Cushing's syndrome, which is associated with excessive absorption of corticosteroids.

Q: What is known about the use of Clobex in patients with liver disease?

Official prescribing information notes that patients with liver failure or existing liver disease may be more prone to the risks of systemic absorption. Liver dysfunction is considered a factor that may predispose a patient to HPA axis suppression.

Q: Does Clobex cause temporary hair loss or changes to hair growth?

Reports from post-marketing experience mention hair loss (alopecia) and, conversely, thinning of the hair or increased hair growth (hypertrichosis) as potential adverse reactions. These reactions are typically related to the topical steroid itself or the underlying condition being treated.

Q: Why is Clobex contraindicated for patients with certain viral or bacterial skin infections?

Official regulatory documents state that the medicine is contraindicated in skin areas affected by certain infections, including bacterial, fungal, or viral diseases. This is because topical steroids suppress the body's local immune response, which can potentially worsen the severity of an existing infection.

Q: How does the super-potency of Clobex relate to its potential side effect risks?

Official warnings explicitly state that the use of more potent steroids like clobetasol propionate is a factor that increases the potential for systemic absorption. This higher rate of absorption directly contributes to the overall risk of systemic side effects, such as HPA axis suppression.

Q: Can Clobex be applied to the scalp without first washing the hair?

The official instructions for Clobex Shampoo state that it should be applied once a day to a dry scalp. There is a specific instruction not to wet the hair before applying this formulation.

Q: What are the signs of excessive absorption of Clobex through the skin?

Signs of excessive systemic absorption or related adrenal gland issues may include unusual symptoms such as stomach pain, persistent tiredness, muscle weakness, unexplained weight loss, loss of appetite, or mood changes. The occurrence of high blood sugar is also a related risk.

How should Clobex be stored and disposed of?

Clobex (clobetasol propionate) storage and disposal instructions are defined by regulatory documents to ensure product stability and safety.

Official Storage and Handling

Requirement Specific Instruction
Storage Temperature Store at Controlled Room Temperature, 68 F to 77 F (20 C to 25 C).
Prohibited Conditions Protect from freezing; specific formulations must not be refrigerated.
Flammability Warning The spray/foam is flammable. Avoid fire, flame, or smoking during and immediately following application.
Container Rule Keep the container tightly closed.
Child Safety The product must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired product should not be disposed of via wastewater or household waste unless instructed otherwise. Disposal must follow local regulations or a community drug take-back program. Specific formulations may require disposal after 4 weeks of first opening.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clobex found in:

A-Z Index: